FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013624970> ?p ?o ?g. }

• W2013624970 endingPage "695" @default.
• W2013624970 startingPage "694" @default.
• W2013624970 abstract "<h3>Background</h3> PRO-MERIT is a FIH, open-label, multicenter, Phase I/IIa trial investigating a liposomal RNA vaccine (BNT112) targeting the prostate cancer tumor-associated antigens (TAAs) kallikrein-2, kallikrein-3, acid phosphatase prostate, homeobox B13 (HOXB13), and NK3 homeobox 1. BNT112 is being investigated as monotherapy and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high risk localized prostate cancer (LPC). <h3>Methods</h3> The trial involves dose titration in mCRPC patients (who have progressed after at least 2 but no more than 3 lines of systemic therapy) with BNT112 monotherapy (Part 1, fully recruited), followed by expansion cohorts (Part 2, recruiting) in both mCPRC and LPC with either BNT112 as monotherapy or in combination with cemiplimab. Primary trial endpoints investigate safety, tolerability, and preliminary anti-tumor activity (by Prostate Cancer Working Group 3 criteria). Secondary endpoints include determination of systemic induction or expansion of vaccine antigen-specific T cells. Vaccine-induced immune responses are analyzed <i>ex vivo</i> using an interferon-γ enzyme-linked immune absorbent spot (ELISpot) assay and following short-term <i>in vitro</i> stimulation. <h3>Results</h3> As of 17 May 2021, 11 patients have received BNT112 monotherapy (9 Part 1; 2 in Part 2) and 3 patients have received BNT112 in combination with cemiplimab (at least one cycle completed). In Part 1, all 9 patients were stage IV at diagnosis and were receiving androgen deprivation therapy. Median age was 68 years. Two out of 9 patients experienced Grade 3 hypertension, leading to one dose reduction, that was initially reported as dose-limiting toxicity (DLT). All recovered within 24 h with no sequelae and the Safety Review Committee eventually concluded the events did not meet the DLT definition. Most common related adverse events (AEs) were pyrexia and hypertension. Eight serious AEs were reported in 5 patients, all unrelated to BNT112. In the 5 patients in Part 2, no additional safety signals or concerns were identified to date, either with BNT112 as monotherapy or in combination with cemiplimab. ELISpot data showed vaccine-induced immune responses were present in 7/7 ELISpot-evaluable patients. All 5 BNT112 TAAs were found to be immunogenic. Responses to each antigen were observed in at least 2 subjects. Initial responses with decreased prostate-specific antigen (PSA) levels have been observed in 2 patients in the BNT112 monotherapy arm. <h3>Conclusions</h3> These data suggest that BNT112 has an acceptable safety profile. Additionally, BNT112 induces robust immune and PSA responses in patients with advanced prostate cancer. <h3>Acknowledgements</h3> The authors would like to acknowledge Camilla West (BioNTech SE) for medical writing support. <h3>Trial Registration</h3> Clinicaltrials. gov: NCT04382898. <h3>Ethics Approval</h3> Ethics & Institutional Review Board approvals were obtained from the respective participating countries prior to initiation of the trial." @default.
• W2013624970 created "2016-06-24" @default.
• W2013624970 creator A5003561684 @default.
• W2013624970 creator A5068074756 @default.
• W2013624970 date "1984-07-01" @default.
• W2013624970 modified "2023-09-27" @default.
• W2013624970 title "Electrically heated gloves in children with Raynaud's phenomenon." @default.
• W2013624970 cites W1578836948 @default.
• W2013624970 cites W1995434825 @default.
• W2013624970 cites W2064790130 @default.
• W2013624970 cites W2075453134 @default.
• W2013624970 cites W2087144690 @default.
• W2013624970 cites W2121480557 @default.
• W2013624970 cites W2435151588 @default.
• W2013624970 doi "https://doi.org/10.1136/adc.59.7.694" @default.
• W2013624970 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1628940" @default.
• W2013624970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6465948" @default.
• W2013624970 hasPublicationYear "1984" @default.
• W2013624970 type Work @default.
• W2013624970 sameAs 2013624970 @default.
• W2013624970 citedByCount "0" @default.
• W2013624970 crossrefType "journal-article" @default.
• W2013624970 hasAuthorship W2013624970A5003561684 @default.
• W2013624970 hasAuthorship W2013624970A5068074756 @default.
• W2013624970 hasBestOaLocation W20136249701 @default.
• W2013624970 hasConcept C16005928 @default.
• W2013624970 hasConcept C2909486431 @default.
• W2013624970 hasConcept C71924100 @default.
• W2013624970 hasConceptScore W2013624970C16005928 @default.
• W2013624970 hasConceptScore W2013624970C2909486431 @default.
• W2013624970 hasConceptScore W2013624970C71924100 @default.
• W2013624970 hasIssue "7" @default.
• W2013624970 hasLocation W20136249701 @default.
• W2013624970 hasLocation W20136249702 @default.
• W2013624970 hasLocation W20136249703 @default.
• W2013624970 hasLocation W20136249704 @default.
• W2013624970 hasOpenAccess W2013624970 @default.
• W2013624970 hasPrimaryLocation W20136249701 @default.
• W2013624970 hasRelatedWork W2044038262 @default.
• W2013624970 hasRelatedWork W2076063045 @default.
• W2013624970 hasRelatedWork W2430150454 @default.
• W2013624970 hasRelatedWork W2435407217 @default.
• W2013624970 hasRelatedWork W2738981461 @default.
• W2013624970 hasRelatedWork W396352011 @default.
• W2013624970 hasRelatedWork W4231464416 @default.
• W2013624970 hasRelatedWork W4234833016 @default.
• W2013624970 hasRelatedWork W4297184974 @default.
• W2013624970 hasRelatedWork W637364136 @default.
• W2013624970 hasVolume "59" @default.
• W2013624970 isParatext "false" @default.
• W2013624970 isRetracted "false" @default.
• W2013624970 magId "2013624970" @default.
• W2013624970 workType "article" @default.